COVID-19 Treatment Guidelines Ivermectin
Table 2c. Ivermectin: Selected Clinical Data (National Institute of Health)
Hydroxychloroquine: Does It Have Clinical Value In COVID-19? A Point, Counterpoint Discussion
Excerpt from Article:
The outcome was a statistically significant (p=.025) 24% reduced risk of COVID-19 infection, hospitalization, and death. The reduced risk was even more significant when only those in one study who started HCQ within two days of exposure were included. The average age of subjects was about 40. Such subjects have a lower risk anyway. But one Spanish study included 293 nursing home residents. In these, HCQ for post-exposure prophylaxis reduced the risk by half. They also looked at side-effects. No serious cardiac adverse events were reported. No arrhythmias were reported in three of the four studies that assessed arrhythmia. A fourth study had one arrhythmia in 936 patients on HCQ and one in 469 controls. There were no serious cardiac effects, and no trial was stopped because of safety concerns. The most common side-effects were gastrointestinal.
MtnClimber wrote: “The outcome was a statistically significant (p=.025) 24% reduced risk of COVID-19 infection, hospitalization, and death.”
Nice but the vaccines have proven to be much more effective: The pfizer vaccine has demonstrated effectiveness against symptomatic illness was 57% after the first dose and 94% after the second, while it was 74% and 87% effective, respectively, at preventing hospitalization. Efficacy was 62% and 92%, respectively, at preventing severe illness and 72% at preventing death 14 to 20 days after the first dose.
Would you prefer 25% chance of an infection or a a 5% risk of an infection?
